Shopping Cart 0
Cart Subtotal
USD 0

Aeglea BioTherapeutics Inc (AGLE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Aeglea BioTherapeutics Inc (Aeglea BioTherapeutics), formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops and commercializes engineered human enzymes for the treatment of cancer and rare genetic diseases. The company's product pipeline comprises AEB1102, AEB3103, AEB2109, and AEB4104. It develops engineered human enzymes to target and degrade amino acids in the blood. Aeglea BioTherapeutics is developing products for the treatment of Arginase I Deficiency; homocystinuria and others. The company works in partnership with research institutions, allied healthcare providers and pharmaceutical companies to discover, develop and market new product candidates. Aeglea BioTherapeutics is headquartered in Austin, Texas, the US.

Aeglea BioTherapeutics Inc (AGLE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Aeglea Biotherapeutics Acquires In-Process R&D Assets from GMA Technologies 11

Venture Financing 12

Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 12

Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 14

Aeglea BioTherapeutics Raises USD 5.1 Million In Venture Financing 15

Partnerships 16

Aeglea BioTherapeutics Enters into Agreement with Merck 16

Licensing Agreements 17

AEMase Enters into Licensing Agreement with University of Texas at Austin 17

Equity Offering 18

Aeglea BioTherapeutics Prices Public Offering of Shares for USD36 Million 18

Aeglea BioTherapeutics Raises USD12.3 Million in Public Offering of Shares 20

Aeglea BioTherapeutics Raises USD54.8 million in IPO 21

Aeglea BioTherapeutics Inc-Key Competitors 22

Aeglea BioTherapeutics Inc-Key Employees 23

Aeglea BioTherapeutics Inc-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

Aug 09, 2018: Aeglea Biotherapeutics provides corporate update and reports second quarter 2018 financial results 25

May 08, 2018: Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results 27

Mar 13, 2018: Aeglea BioTherapeutics Reports Q4 and Full Year 2017 Financial Results 29

Nov 07, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results 30

Aug 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results 31

May 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results 32

Mar 23, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results 33

Corporate Communications 35

Jul 16, 2018: Aeglea BioTherapeutics names Dr. Bryan Lawlis as board director 35

Jul 20, 2017: Aeglea BioTherapeutics Announces Leadership Change 36

Jul 10, 2017: Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer 37

Feb 16, 2017: Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors 38

Product News 39

11/29/2017: Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102) 39

09/06/2017: Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency 40

05/23/2017: Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update 41

04/03/2018: Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting 43

03/26/2018: Aeglea BioTherapeutics Appoints Dr. Ivana Magovcevic-Liebisch to Board of Directors 44

03/13/2018: Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency 45

03/06/2018: Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic Disorders 47

02/28/2017: Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at Keystone Symposia Conference on Tumor Metabolism 48

Clinical Trials 49

Apr 05, 2018: Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting 49

Apr 02, 2018: Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA (Pembrolizumab) Combination Trials 50

Mar 08, 2018: Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase 51

Jan 18, 2018: Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism Conference 52

Nov 02, 2017: Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting 53

Mar 29, 2017: Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting 54

Mar 23, 2017: Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting 55

Jan 17, 2017: Aeglea BioTherapeutics to Present New Data at 2017 ACMG Annual Clinical Genetics Meeting 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57


List Of Figure

List of Figures

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aeglea BioTherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aeglea Biotherapeutics Acquires In-Process R&D Assets from GMA Technologies 11

Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 12

Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 14

Aeglea BioTherapeutics Raises USD 5.1 Million In Venture Financing 15

Aeglea BioTherapeutics Enters into Agreement with Merck 16

AEMase Enters into Licensing Agreement with University of Texas at Austin 17

Aeglea BioTherapeutics Prices Public Offering of Shares for USD36 Million 18

Aeglea BioTherapeutics Raises USD12.3 Million in Public Offering of Shares 20

Aeglea BioTherapeutics Raises USD54.8 million in IPO 21

Aeglea BioTherapeutics Inc, Key Competitors 22

Aeglea BioTherapeutics Inc, Key Employees 23

Aeglea BioTherapeutics Inc, Subsidiaries 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Aeglea BioTherapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Aeglea BioTherapeutics Inc (Aeglea BioTherapeutics), formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops and commercializes engineered human enzymes for the treatment of cancer and rare genetic diseases. The company's product pipeline comprises AEB1102, AEB3103, AEB2109, and AEB4104. It develops engineered human enzymes to target and degrade amino acids in the blood. Aeglea BioTherapeutics is developing products for the treatment of Arginase I Deficiency; homocystinuria and others. The company works in partnership with research institutions, allied healthcare providers and pharmaceutical companies to discover, develop and market new product candidates. Aeglea BioTherapeutics is headquartered in Austin, Texas, the US.

Aeglea BioTherapeutics Inc (AGLE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Aeglea Biotherapeutics Acquires In-Process R&D Assets from GMA Technologies 11

Venture Financing 12

Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 12

Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 14

Aeglea BioTherapeutics Raises USD 5.1 Million In Venture Financing 15

Partnerships 16

Aeglea BioTherapeutics Enters into Agreement with Merck 16

Licensing Agreements 17

AEMase Enters into Licensing Agreement with University of Texas at Austin 17

Equity Offering 18

Aeglea BioTherapeutics Prices Public Offering of Shares for USD36 Million 18

Aeglea BioTherapeutics Raises USD12.3 Million in Public Offering of Shares 20

Aeglea BioTherapeutics Raises USD54.8 million in IPO 21

Aeglea BioTherapeutics Inc-Key Competitors 22

Aeglea BioTherapeutics Inc-Key Employees 23

Aeglea BioTherapeutics Inc-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

Aug 09, 2018: Aeglea Biotherapeutics provides corporate update and reports second quarter 2018 financial results 25

May 08, 2018: Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results 27

Mar 13, 2018: Aeglea BioTherapeutics Reports Q4 and Full Year 2017 Financial Results 29

Nov 07, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results 30

Aug 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results 31

May 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results 32

Mar 23, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results 33

Corporate Communications 35

Jul 16, 2018: Aeglea BioTherapeutics names Dr. Bryan Lawlis as board director 35

Jul 20, 2017: Aeglea BioTherapeutics Announces Leadership Change 36

Jul 10, 2017: Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer 37

Feb 16, 2017: Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors 38

Product News 39

11/29/2017: Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102) 39

09/06/2017: Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency 40

05/23/2017: Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update 41

04/03/2018: Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting 43

03/26/2018: Aeglea BioTherapeutics Appoints Dr. Ivana Magovcevic-Liebisch to Board of Directors 44

03/13/2018: Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency 45

03/06/2018: Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic Disorders 47

02/28/2017: Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at Keystone Symposia Conference on Tumor Metabolism 48

Clinical Trials 49

Apr 05, 2018: Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting 49

Apr 02, 2018: Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA (Pembrolizumab) Combination Trials 50

Mar 08, 2018: Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase 51

Jan 18, 2018: Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism Conference 52

Nov 02, 2017: Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting 53

Mar 29, 2017: Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting 54

Mar 23, 2017: Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting 55

Jan 17, 2017: Aeglea BioTherapeutics to Present New Data at 2017 ACMG Annual Clinical Genetics Meeting 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57


List Of Figure

List of Figures

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aeglea BioTherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aeglea Biotherapeutics Acquires In-Process R&D Assets from GMA Technologies 11

Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 12

Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 14

Aeglea BioTherapeutics Raises USD 5.1 Million In Venture Financing 15

Aeglea BioTherapeutics Enters into Agreement with Merck 16

AEMase Enters into Licensing Agreement with University of Texas at Austin 17

Aeglea BioTherapeutics Prices Public Offering of Shares for USD36 Million 18

Aeglea BioTherapeutics Raises USD12.3 Million in Public Offering of Shares 20

Aeglea BioTherapeutics Raises USD54.8 million in IPO 21

Aeglea BioTherapeutics Inc, Key Competitors 22

Aeglea BioTherapeutics Inc, Key Employees 23

Aeglea BioTherapeutics Inc, Subsidiaries 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Aeglea BioTherapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.